Excelsior Biopharma (TWO:6496) — Market Cap & Net Worth
Market Cap & Net Worth: Excelsior Biopharma (6496)
Excelsior Biopharma (TWO:6496) has a market capitalization of $36.17 Million (NT$1.15 Billion) as of September 17, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #23194 globally and #1438 in its home market, demonstrating a 0.82% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Excelsior Biopharma's stock price NT$24.65 by its total outstanding shares 46578000 (46.58 Million). Also see Excelsior Biopharma asset portfolio for a full breakdown of the balance sheet.
Excelsior Biopharma Market Cap History: 2015 to 2026
Excelsior Biopharma's market capitalization history from 2015 to 2026. Data shows change from $199.57 Million to $36.17 Million (-7.16% CAGR). Also see how efficiently does Excelsior Biopharma generate cash for how efficiently the company converts equity into cash flow.
Excelsior Biopharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Excelsior Biopharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 6496 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.05x
Excelsior Biopharma's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $108.45 Million | $1.72 Billion | $279.68 Million | 0.06x | 0.39x |
| 2018 | $59.65 Million | $1.69 Billion | $221.83 Million | 0.04x | 0.27x |
| 2019 | $52.39 Million | $1.54 Billion | $71.01 Million | 0.03x | 0.74x |
| 2020 | $43.51 Million | $1.44 Billion | $35.30 Million | 0.03x | 1.23x |
| 2021 | $42.92 Million | $1.34 Billion | -$15.65 Million | 0.03x | N/A |
| 2022 | $40.80 Million | $671.76 Million | -$33.76 Million | 0.06x | N/A |
| 2023 | $42.34 Million | $771.56 Million | -$91.01 Million | 0.05x | N/A |
| 2024 | $43.95 Million | $861.91 Million | -$98.70 Million | 0.05x | N/A |
| 2025 | $42.92 Million | $898.26 Million | -$183.17 Million | 0.05x | N/A |
Competitor Companies of 6496 by Market Capitalization
Companies near Excelsior Biopharma in the global market cap rankings as of September 17, 2026. Review 6496 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Excelsior Biopharma by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #519 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #633 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #640 globally with a market cap of $43.16 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.62 Billion USD ( CN¥277.61 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #519 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #633 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #640 | GALDERMA GROUP AG | NYSE:GALDY | $43.16 Billion | $37.02 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.62 Billion | CN¥43.52 |
Excelsior Biopharma Historical Marketcap From 2015 to 2026
Between 2015 and today, Excelsior Biopharma's market cap moved from $199.57 Million to $ 36.17 Million, with a yearly change of -7.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$36.17 Million | -15.73% |
| 2025 | NT$42.92 Million | -2.34% |
| 2024 | NT$43.95 Million | +3.81% |
| 2023 | NT$42.34 Million | +3.78% |
| 2022 | NT$40.80 Million | -4.96% |
| 2021 | NT$42.92 Million | -1.35% |
| 2020 | NT$43.51 Million | -16.95% |
| 2019 | NT$52.39 Million | -12.18% |
| 2018 | NT$59.65 Million | -44.99% |
| 2017 | NT$108.45 Million | +17.30% |
| 2016 | NT$92.45 Million | -53.68% |
| 2015 | NT$199.57 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Excelsior Biopharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.17 Million USD |
| MoneyControl | $36.17 Million USD |
| MarketWatch | $36.17 Million USD |
| marketcap.company | $36.17 Million USD |
| Reuters | $36.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Excelsior Biopharma
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specia… Read more